The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation

被引:19
作者
Kavanagh, D.
Burgess, R.
Spitzer, D.
Richards, A.
Diaz-Torres, M. L.
Goodship, J. A.
Hourcade, D. E.
Atkinson, J. P.
Goodship, T. H. J. [1 ]
机构
[1] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[2] Washington Univ, Sch Med, St Louis, MO 63110 USA
关键词
hemolytic uremic syndrome; complement; decay accelerating factor (DAF); factor I (CFI); factor H (CFH); membrane cofactor protein (MCP);
D O I
10.1016/j.molimm.2007.01.036
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hemolytic uremic syndrome is the clinical triad of thrombocytopenia, microangiopathic hemolytic anaemia and acute renal failure. Cases not associated with a preceding Shiga-like toxin producing Escherichia coli are described as atypical HUS (aHUS). Approximately 50% of patients with aHUS have mutations in one of three complement regulatory proteins, Factor H (CFH), membrane cofactor protein (MCP;CD46) or factor I (IF). A common feature of these three proteins is that they regulate complement by cofactor activity. Decay accelerating factor (DAF; CD55) regulates the complement system by disassociating the alternative and classical pathway convertases. Like CFH and MCP, the gene for DAF lies within the regulators of complement activation (RCA) gene cluster at 1q32. In 1998, we described linkage to this region in families with allUS which led to the discovery of mutations in CFH and MCP. We therefore genotyped DAF in a panel of 46 allUS patients including families with linkage to the RCA cluster. A mutation, I197V, was identified in one patient with familial HUS which was not found in 100 healthy controls. Molecular modelling of this mutation shows that the I197V mutation does not reside in an area which would be predicted to be important in decay accelerating activity. The expression of I197V on EBV-transformed B lymphocytes was equivalent to that of wild type controls. There was no significant decrease in decay acceleration activity of the recombinantly produced I197V mutant compared with wild type, as measured by a complement- mediated lytic assay. In conclusion, this study, identifies only one mutation in DAF in 46 patients with allUS. This mutation, I197V, does not impair complement regulation and cannot be implicated in the pathogenesis of allUS in this patient. This suggests that the complement regulatory abnormality in aHUS is principally one of deficient cofactor activity rather than of decay acceleration activity. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3162 / 3167
页数:6
相关论文
共 32 条
[1]  
Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
[2]   Genetics of HUS:: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome [J].
Caprioli, Jessica ;
Noris, Marina ;
Brioschi, Simona ;
Pianetti, Gaia ;
Castelletti, Federica ;
Bettinaglio, Paola ;
Mele, Caterina ;
Bresin, Elena ;
Cassis, Linda ;
Gamba, Sara ;
Porrati, Francesca ;
Bucchioni, Sara ;
Monteferrante, Giuseppe ;
Fang, Celia J. ;
Liszewski, M. K. ;
Kavanagh, David ;
Atkinson, John P. ;
Remuzzi, Giuseppe .
BLOOD, 2006, 108 (04) :1267-1279
[3]   A POSSIBLE NULL PHENOTYPE IN THE CROMER BLOOD-GROUP COMPLEX [J].
DANIELS, GL ;
TOHYAMA, H ;
UCHIKAWA, M .
TRANSFUSION, 1982, 22 (05) :362-363
[4]  
Daniels GL, 1998, TRANSFUSION MED, V8, P141
[5]   Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome [J].
Dragon-Durey, MA ;
Loirat, C ;
Cloarec, S ;
Macher, MA ;
Blouin, J ;
Nivet, H ;
Weiss, L ;
Fridman, WH ;
Frémeaux-Bacchi, V .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :555-563
[6]   Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis:: Report and genetic analysis of 16 cases [J].
Dragon-Durey, MA ;
Frémeaux-Bacchi, V ;
Loirat, C ;
Blouin, J ;
Niaudet, P ;
Deschenes, G ;
Coppo, P ;
Fridman, WH ;
Weiss, L .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :787-795
[7]   Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32 [J].
Esparza-Gordillo, J ;
de Jorge, EG ;
Buil, A ;
Berges, LC ;
López-Trascasa, M ;
Sánchez-Corral, P ;
de Córdoba, SR .
HUMAN MOLECULAR GENETICS, 2005, 14 (05) :703-712
[8]   CHARACTERIZATION OF THE DECAY-ACCELERATING FACTOR GENE PROMOTER REGION [J].
EWULONU, UK ;
RAVI, L ;
MEDOF, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) :4675-4679
[9]   Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome [J].
Fremeaux-Bacchi, V ;
Dragon-Durey, MA ;
Blouin, J ;
Vigneau, C ;
Kuypers, D ;
Boudailliez, B ;
Loirat, C ;
Rondeau, E ;
Fridman, WH .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) :e84
[10]   Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome [J].
Fremeaux-Bacchi, Veronique ;
Moulton, Elizabeth A. ;
Kavanagh, David ;
Dragon-Durey, Marie-Agnes ;
Blouin, Jacques ;
Caudy, Amy ;
Arzouk, Nadia ;
Cleper, Roxanna ;
Francois, Maud ;
Guest, Genevieve ;
Pourrat, Jacques ;
Seligman, Roland ;
Fridman, Wolf Herman ;
Loirat, Chantal ;
Atkinson, John P. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (07) :2017-2025